CollPlant Biotechnologies Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.4M+360.4% YoYTTM through 31 Dec 2025
Net Income -$11.5MTTM through 31 Dec 2025
Free Cash Flow -$9.4MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 64.8% |
| EBITDA Margin | -445.8% |
| Operating Margin | -484.3% |
| Net Margin | -484.6% |
Returns
-188.9%ROE
-106.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.53x
Net Debt-$5.6Mnet cash position
Cash & Equivalents$5.6M
Quality Metrics
Altman Z-Score-18.12
Piotroski F-Score4 / 9
FCF Margin-398.4%
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $2.4M
Diluted EPS-$0.94TTMFY2025: $-0.94
Dividend
No dividend
Capital Allocation
Capex Intensity1.2%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.